<code id='3B96D09613'></code><style id='3B96D09613'></style>
    • <acronym id='3B96D09613'></acronym>
      <center id='3B96D09613'><center id='3B96D09613'><tfoot id='3B96D09613'></tfoot></center><abbr id='3B96D09613'><dir id='3B96D09613'><tfoot id='3B96D09613'></tfoot><noframes id='3B96D09613'>

    • <optgroup id='3B96D09613'><strike id='3B96D09613'><sup id='3B96D09613'></sup></strike><code id='3B96D09613'></code></optgroup>
        1. <b id='3B96D09613'><label id='3B96D09613'><select id='3B96D09613'><dt id='3B96D09613'><span id='3B96D09613'></span></dt></select></label></b><u id='3B96D09613'></u>
          <i id='3B96D09613'><strike id='3B96D09613'><tt id='3B96D09613'><pre id='3B96D09613'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge